
Access to Semaglutide, Tirzepatide for Obesity Not Equal for All
Significant disparities and low prescribing rates of semaglutide and tirzepatide for obesity from 2021 through 2024 highlight that there may be potential links to the social factors of race, ethnicity, social vulnerability, urbanicity, and underutilization …